Table 7.

Patients presented hypersensitivity

	Adverse reaction	Association	Severity	Outcome	time to onset (days)	Sex	Age (year)	Complications	Concomitant suspected products †	Comment from physicians
1	Hypersensitivity	Associated	Not serious	Ameliorated	6	Male	30
2	Erythema multiforme	Associated	Serious	Ameliorated	8	Female	32	Hepatitis C Gastric ulcer	ddI, d4T	Association with ddI and d4T cannot be ruled out
3	Rash/Pyrexia	Not ruled out/Definitely associated	Not serious	Ameliorated	9	Male	37	Hemophilia A Hepatitis C	NVP
4	Drug eruption/Myalgia	Definitely associated/Not ruled out	Not serious	Recovered	11/13	Female	63		d4T, EFV, 3TC
5	Rash, Pyrexia	Not ruled out	Serious	Recovered	57	Male	31	Hepatitis C Hemophilia A	NVP	Association with NVP cannot be ruled out
6	Upper respiratory tract inflammation	Not ruled out	Not serious	Recovered	13	Male	23	Hemophilia B Hepatitis C
7	Rash, Headache/Anorexia	Associated/Not ruled out	Not serious	Ameliorated	2	Male	36	Hepatitis B Syphilis	AZT/3TC
8	Drug hypersensitivity	Associated	Not serious	Recovered	20	Male	44
9	Rash	Not ruled out	Not serious	Ameliorated	10	Male	38		EFV,LPV/rtv	Association with EFV and LPV/rtv could not be ruled out
10	Pyrexia, vomiting and diarrhea	Not ruled out	Not serious	Ameliorated	12	Male	34		AZT/3TC
11	Pyrexia, Myalgia, Abdominal pain	Associated	Serious	Recovered	2	Male	39	Hepatitis C Hemophilia B		The symptoms were improved after changing ABC to ddI
12	Queasy, Pyrexia, Myalgia	Associated	Not serious	Recovered	1	Male	35	Hepatitis B Syphilis		The symptoms disappeared after discontinuation of ABC
13	Drug hypersensitivity	Associated	Not serious	Recovered	16	Male	62	Hypertension
14	Rash, Conjunctival hyperemia, Pyrexia	Definitely associated	Not serious	Ameliorated	11	Male	31
15	Drug eruption	Associated	Serious	Ameliorated	12	Female	60s	Hypertension

^†ddI, didanosine; d4T, stavudine; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine; LPV/rtv, lopinavir/ritonavir; TDF, tenofovir disoproxil fumarate; EFV, efavirenz.